Preclinical Evaluation of Caprylic Acid-Fractionated IgG Antivenom for the Treatment of Taipan (Oxyuranus scutellatus) Envenoming in Papua New Guinea
Open Access
- 17 May 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 5 (5) , e1144
Abstract
Snake bite is a common medical emergency in Papua New Guinea (PNG). The taipan, Oxyuranus scutellatus, inflicts a large number of bites that, in the absence of antivenom therapy, result in high mortality. Parenteral administration of antivenoms manufactured in Australia is the current treatment of choice for these envenomings. However, the price of these products is high and has increased over the last 25 years; consequently the country can no longer afford all the antivenom it needs. This situation prompted an international collaborative project aimed at generating a new, low-cost antivenom against O. scutellatus for PNG. A new monospecific equine whole IgG antivenom, obtained by caprylic acid fractionation of plasma, was prepared by immunising horses with the venom of O. scutellatus from PNG. This antivenom was compared with the currently used F(ab')2 monospecific taipan antivenom manufactured by CSL Limited, Australia. The comparison included physicochemical properties and the preclinical assessment of the neutralisation of lethal neurotoxicity and the myotoxic, coagulant and phospholipase A2 activities of the venom of O. scutellatus from PNG. The F(ab')2 antivenom had a higher protein concentration than whole IgG antivenom. Both antivenoms effectively neutralised, and had similar potency, against the lethal neurotoxic effect (both by intraperitoneal and intravenous routes of injection), myotoxicity, and phospholipase A2 activity of O. scutellatus venom. However, the whole IgG antivenom showed a higher potency than the F(ab')2 antivenom in the neutralisation of the coagulant activity of O. scutellatus venom from PNG. The new whole IgG taipan antivenom described in this study compares favourably with the currently used F(ab')2 antivenom, both in terms of physicochemical characteristics and neutralising potency. Therefore, it should be considered as a promising low-cost candidate for the treatment of envenomings by O. scutellatus in PNG, and is ready to be tested in clinical trials.Keywords
This publication has 51 references indexed in Scilit:
- Randomised Controlled Double-Blind Non-Inferiority Trial of Two Antivenoms for Saw-Scaled or Carpet Viper (Echis ocellatus) Envenoming in NigeriaPLOS Neglected Tropical Diseases, 2010
- Variations in the pharmacological profile of post-synaptic neurotoxins isolated from the venoms of the Papuan (Oxyuranus scutellatus canni) and coastal (Oxyuranus scutellatus scutellatus) taipansNeuroToxicology, 2010
- Mass spectrometry analysis of the phospholipase A2 activity of snake pre‐synaptic neurotoxins in cultured neuronsJournal of Neurochemistry, 2009
- Development and validation of a reverse phase HPLC method for the determination of caprylic acid in formulations of therapeutic immunoglobulins and its application to antivenom productionBiologicals, 2009
- Neurotoxicity and Other Pharmacological Activities of the Snake Venom Phospholipase A2OS2: The N-Terminal Region Is More Important Than Enzymatic ActivityBiochemistry, 2006
- Neuromuscular effects of papuan taipan snake venomAnnals of Neurology, 1995
- Phospholipases in snake venoms and their effects on nerve and musclePharmacology & Therapeutics, 1985
- A study of the major australian snake venoms in the monkey (Macaca fascicularis): II. Myolytic and haematological effects of venomsPathology, 1981
- Characterization of the prothrombin activator from the venom of Oxyuranus scutellatus scutellatus (taipan venom)Biochemistry, 1980
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970